

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2022 (the “**Year**”), the Group is expected to record a profit attributable to the owners of the parent of not less than HK\$36 million (2021: loss of HK\$19.6 million) for the Year.

Based on the information available to the Board, the Board considers such expected increase was mainly attributable to (i) the fact that in 2022, the Company continued to improve its marketing capabilities, increased its efforts in market development, and expanded sales channels. The sales of pipeline products continued to grow. Driven by the policies on centralized procurement and regional joint centralized procurement, the coverage of terminal hospitals for selected products of the Company increased gradually, and the related drugs in the field of antibacterial and diabetes increased significantly, driving the growth of the Company’s main business performance, and (ii) entering into bioequivalence studies of a PTH Liquid developed by the Company for treatment of osteoporosis since July 2022, since then related R&D expense met the requirements of accounting capitalization and was included in the capitalized amount of HK\$17.49 million.

* For identification purpose only

As at the date of this announcement, the Company is still in the course of preparing the annual results of the Group for the Year. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for the Year, which have not been reviewed by the Company's auditors or the audit committee of the Board. Such financial information will be subject to finalisation and necessary adjustments. The annual results of the Group for the Year are expected to be announced by the Company before the end of March 2023. Shareholders and potential investors are advised to read the annual results announcement of the Company when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 6 March 2023

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.